Physician profile

Jad Harb

Pulmonary Disease · Anderson, IN

NPI 1467685677

$2,062.59

in general payments reported to CMS, 2019-2025

31 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$162.16

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $280.38 2019-2022
Regeneron Healthcare Solutions, INC. $248.89 2019-2022
Astrazeneca Pharmaceuticals LP $240.04 2019-2022
Boehringer Ingelheim Pharmaceuticals, INC. $190.20 2019-2022
Abbvie INC. $162.16 2023-2024
Janssen Pharmaceuticals, INC $79.22 2019-2022
Jazz Pharmaceuticals INC. $72.78 2019-2022
Merck Sharp & Dohme LLC $71.25 2019-2022
Grifols USA, LLC $70.09 2019-2020
Genzyme Corporation $56.70 2020-2022
Mylan Specialty L.P. $55.69 2019-2022
Genentech USA, INC. $52.57 2019
Philips North America LLC $47.68 2019-2022
Electromed, INC. $45.43 2019-2022
Mallinckrodt Hospital Products INC. $44.65 2020-2022
Show all 31 companies

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jad Harb

$2,062.59

in general payments reported 2019-2025

Years
2019-2024
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/1350107/jad-harb

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.